Scientific article
Open access

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma

Published inJournal of clinical oncology, vol. 30, no. 5, p. 482-487
Publication date2012

Complete remission (CR) is uncommon during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs), but it may occur in some patients. It remains a matter of debate whether therapy should be continued after CR.

  • Adult
  • Aged
  • Antineoplastic Agents/therapeutic use
  • Benzenesulfonates/therapeutic use
  • Carcinoma, Renal Cell/drug therapy/secondary/surgery
  • Feasibility Studies
  • Female
  • Humans
  • Indoles/therapeutic use
  • Kidney Neoplasms/drug therapy/pathology/surgery
  • Male
  • Medical Records
  • Middle Aged
  • Molecular Targeted Therapy
  • Nephrectomy
  • Niacinamide/analogs & derivatives
  • Phenylurea Compounds
  • Protein Kinase Inhibitors/therapeutic use
  • Protein-Tyrosine Kinases/antagonists & inhibitors
  • Pyridines/therapeutic use
  • Pyrroles/therapeutic use
  • Questionnaires
  • Remission Induction
  • Retrospective Studies
  • Treatment Outcome
Citation (ISO format)
ALBIGES, Laurence et al. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. In: Journal of clinical oncology, 2012, vol. 30, n° 5, p. 482–487. doi: 10.1200/JCO.2011.37.2516
Main files (1)
Article (Published version)
ISSN of the journal0732-183X

Technical informations

Creation12/16/2014 7:38:00 AM
First validation12/16/2014 7:38:00 AM
Update time03/14/2023 10:28:19 PM
Status update03/14/2023 10:28:19 PM
Last indexation01/16/2024 3:15:41 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack